EUVIMEDEUVIMED entdecken
Open Access

Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands

Marc Andrea Walser iD, Nicolas Bachmann, Jonas Kluckert, A Köthe, Carson Tully, Dominic Leiser, Antony John Lomax, Nicola Bizzocchi, Johannes Albertus Langendijk, Damien C Weber

The British Journal of Radiology · 2023

DOI: 10.1259/bjr.20220672 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The British Journal of Radiology, 2023. Verfasst von Marc Andrea Walser und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232 Villigen, Switzerland. Hauptthemen laut MEDLINE: Proton Therapy, Deglutition Disorders, Radiotherapy, Intensity-Modulated, Xerostomia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The purpose of this study is to report the oncological outcome, observed toxicities and normal tissue complication probability (NTCP) calculation for pencil beam scanning (PBS) PT delivered to salivary gland tumour (SGT) patients.

Methods

We retrospectively reviewed 26 SGT patients treated with PBSPT (median dose, 67.5 Gy(RBE)) between 2005 and 2020 at our institute. Toxicities were recorded according to CTCAEv.4.1. Overall survival (OS), local control (LC), locoregional control (LRC) and distant control (DC) were estimated. For all patients, a photon plan was re-calculated in order to assess the photon/proton NTCP.

Results

With a median follow-up time of 46 months (range, 3–118), 5 (19%), 2 (8%), 3 (12%) and 2 (8%) patients presented after PT with distant, local, locoregional failures and death, respectively. The estimated 4 year OS, LC, LCR and DC were 90%, 90%, 87 and 77%, respectively. Grade 3 late toxicity was observed in 2 (8%) patients. The estimated 4 year late high-grade (≥3) toxicity-free survival was 78.4%. The calculated mean difference of NTCP-values after PBSPT and VMAT plans for developing Grade 2 or 3 xerostomia were 3.8 and 2.9%, respectively. For Grade 2–3 dysphagia, the grade corresponding percentages were 8.6 and 1.9%. Not using an up-front model-based approach to select patients for PT, only 40% of our patients met the Dutch eligibility criteria.

Conclusion

Our data suggest excellent oncological outcome and low late toxicity rates for patients with SGT treated with PBSPT. NTCP calculation showed a substantial risk reduction for Grade 2 or 3 xerostomia and dysphagia in some SGT patients, while for others, no clear benefit was seen with protons, suggesting that comparative planning should be performed routinely for these patients. Advances in knowledge We have reported that the clinical outcome of SGT patients treated with PT and compared IMPT to VMAT for the treatment of salivary gland tumour and have observed that protons delivered significantly less dose to organs at risks and were associated with less NTCP for xerostomia and dysphagia. Noteworthy, not using an up-front model-based approach, only 40% of our patients met the Dutch eligibility criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton TherapyDeglutition DisordersRadiotherapy, Intensity-ModulatedXerostomiaOropharyngeal NeoplasmsHumansProtonsRetrospective StudiesSalivary GlandsProbabilityRadiotherapy Planning, Computer-AssistedRadiotherapy Dosage

Substanzen

Protons

Autor:innen und Institutionen

  • Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232 Villigen, Switzerland.
  • Department of Radiation Oncology, lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Physics, ETH Zurich, Zurich, Switzerland.
  • Department of Radiation Oncology, University of Groningen, Groningen, The Netherlands.
  • Department of Radiation Oncology, University Hospital of Zürich, Zürich, Switzerland.

ORCID-Profile: Marc Andrea Walser

Zitieren

APA

Walser, M. A., Bachmann, N., Kluckert, J., Köthe, A., Tully, C., Leiser, D., Lomax, A. J., Bizzocchi, N., Langendijk, J. A., & Weber, D. C. (2023). Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands. The British Journal of Radiology. https://doi.org/10.1259/bjr.20220672

Vancouver

Walser MA, Bachmann N, Kluckert J, Köthe A, Tully C, Leiser D, et al. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands. The British Journal of Radiology. 2023. doi:10.1259/bjr.20220672

BibTeX
@article{Walser2023,
  author = {Walser, Marc Andrea and Bachmann, Nicolas and Kluckert, Jonas and Köthe, A and Tully, Carson and Leiser, Dominic and Lomax, Antony John and Bizzocchi, Nicola and Langendijk, Johannes Albertus and Weber, Damien C},
  title = {Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands},
  journal = {The British Journal of Radiology},
  year = {2023},
  doi = {10.1259/bjr.20220672}
}
Kostenlos starten →